Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Geron (Nasdaq: GERN) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 11:00 a.m. ET. A live audio webcast and archived audio will be available via the Investors & Media section at geron.com.
Details
News Market Reaction – GERN
On Apr 6, the day this news came out, GERN closed 5.42% above the previous close.
Data tracked by StockTitan Argus for the Apr 6 session.
Key Figures
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference
- Conference date
- April 13, 2026
- Scheduled fireside chat
- Event time
- 11:00 a.m. ET
- Start time of fireside chat
Historical Context
-
Added two experienced biopharma leaders to support RYTELO commercial strategy.
-
Granted 956,250 stock options to six new hires under inducement plan.
-
Reported strong RYTELO revenue, cash of $401.1M, and reiterated 2026 guidance.
-
Announced March investor conference appearances with webcast access for investors.
-
Issued 742,500 stock options to a new hire with 10-year term and vesting schedule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.
A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.